Ibex Medical Analytics

Company Overview

Snapshot

Founded in January 2016 by Joseph (Yossi) Mossel and Chaim Linhart, Ibex Medical Analytics operates with 51–200 employees. The company has raised $116.6 million across 5 funding rounds from 10 investors. In September 2023, Ibex Medical Analytics secured a Series C funding round, with 83North participating as a lead investor.

Business overview

Ibex Medical Analytics develops clinical-grade solutions for cancer detection using artificial intelligence. Its core product, the Galen platform, employs algorithms to analyze images, detect and grade cancer in biopsies, and identify clinically significant findings, aiming to reduce diagnostic errors and enhance workflow efficiency for pathologists. The company's Galen Prostate and Galen Breast are AI-based cancer detection solutions deployed in routine clinical practice globally. Ibex Medical Analytics also focuses on developing computational prognostic and predictive tests to improve patient stratification and personalize treatment selection, serving the health tech and life sciences sector.

Strategic signal

In September 2023, Ibex Medical Analytics raised $55 million in Series C funding. This significant capital injection underscores investor confidence in the company's AI-powered cancer diagnostics technology and its potential for market expansion and further product development, signaling a strong growth trajectory and continued innovation in the digital pathology space.

Company Intelligence Q&A

What was the most recent funding round for Ibex Medical Analytics?

In September 2023, Ibex Medical Analytics raised $55 million in a Series C funding round. 83North participated as a lead investor, with additional participation from.

When did Ibex Medical Analytics secure funding from Kreos Capital?

In November 2022, Ibex Medical Analytics secured $10 million in funding from Kreos Capital.

What was a key strategic partnership announced by Ibex Medical Analytics in March 2022?

In March 2022, Ibex Medical Analytics announced a strategic partnership with Dedalus to integrate artificial intelligence into digital pathology workflows.

When did Ibex Medical Analytics receive FDA Breakthrough Device Designation?

In June 2021, Ibex Medical Analytics was granted FDA Breakthrough Device Designation.

What was a significant product development milestone for Ibex Medical Analytics in September 2022?

In September 2022, Ibex Medical Analytics announced the launch of its Galen™ 3.0 Cancer Diagnostics Platform, enhancing its AI-powered capabilities for cancer detection.